In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins

Journal of Infectious Diseases

Volumn 189, Issue 8, 2004, Pages 1440-1443

  Barrientos, Laura G ^a   Lasala, Fatima ^b   Otero, Joaquin R ^b   Sanchez, Anthony ^a   Delgado, Rafael ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOVIRIN N; LENTIVIRUS VECTOR;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; EBOLA ZAIRE VIRUS; EBOLA ZAIRE VIRUS INFECTION; ENVELOPE GENE; FILOVIRUS; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LENTIVIRINAE; MARBURG VIRUS; PRIORITY JOURNAL; VIRUS INFECTION;

ANTIVIRAL AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; EBOLAVIRUS; GLYCOPROTEINS; HELA CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; JURKAT CELLS; LENTIVIRUS; MARBURG VIRUS DISEASE; MARBURGVIRUS; TRANSDUCTION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 2142653012     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/382658     Document Type: Article

References (15)

1. Feldmann H, Volchkov VE, Volchkova VA, Klenk HD. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 1999; 15:159-69.
2. Alvarez CP, Lasala F, Carrillo J, Muñez O, Corbí AL, Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002; 76:6841-4.
3. Baribaud F, Doms RW, Pohlmann S. Review article: The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination? Expert Opin Ther Targets 2002; 6:423-31.
4. 1,2 and inhibits infectivity of Ebola virus. Antiviral Res 2003; 58:47-56.
5. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41: 1521-30.
6. O'Keefe BR, Smee DF, Turpin JA, et al. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 2003; 47:2518-25.
7. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000; 74:4562-9.
8. Shenoy SR, Barrientos LG, Ratner DM, et al. Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization. Chem Biol 2002; 9:1109-18.
9. Barrientos LG, Gronenborn AM. Review article: The highly specific carbohydrate binding protein cyanovirin-N: structure anti-HIV/Ebola activity and possibilities for therapy. Mini Rev Med Chem (in press).
10. Sanders DA. Review article: No false start for novel pseudotyped vectors. Curr Opin Biotechnol 2002; 13:437-42.
11. Mori T, Barrientos LG, Han Z, Gronenborn AM, Turpin JA, Boyd MR. Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. Protein Expr Purif 2002; 26:42-9.
12. Yang S, Delgado R, King SR, et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999; 10: 123-32.
13. He J, Cho S, Walker R, di Marzio P, Morgan DO,Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995; 69:6705-11.
14. Feinberg H, Mitchell DA, Drickamer K, Weis WI. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001; 294:2163-6.
15. Scanlan CN, Pantophlet R, Wormald MR, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J Virol 2002; 76:7306-7321.